Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse). Following the acquisition of CellRight in 2017, TRX revised its commercial strategy, to service the strong demand for its products. However, this necessitated capacity expansion and realignment of its supply chain, which affected 2019 tradin
06 Feb 2020
Restructured to satisfy product demand
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Restructured to satisfy product demand
Tissue Regenix Group plc (TRX:LON) | 61.5 0 0.0% | Mkt Cap: 43.4m
- Published:
06 Feb 2020 -
Author:
Martin Hall -
Pages:
12
Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse). Following the acquisition of CellRight in 2017, TRX revised its commercial strategy, to service the strong demand for its products. However, this necessitated capacity expansion and realignment of its supply chain, which affected 2019 tradin